As big pharmas including Takeda and Novo Nordisk flee the cell therapy space and smaller biotechs shutter their operations, these players are sticking around to take the modality as far as it can go.

In the dynamic landscape of oncology, drug development presents towering challenges. Historically marked by high attrition ...

New advisory mechanisms and revised family cost norms are explored to refine wage calculations as disparities across states fuel calls for a more equitable and flexible floor wage system ...

Bristol Myers Squibb has struggled over the past few years due to patent cliffs. And to make matters worse, it will soon face even more, including for two of its best-selling medicines, cancer drug ...

Speculation about public sector bank mergers has surfaced again. The jury is out on the efficacy of the last round of mergers ...

CEO Will Bruey says people often get Varda wrong. The company isn't "in the space industry; we're in-space industry," he said ...